<DOC>
	<DOCNO>NCT00602706</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth cancer cell either kill cell stop dividing . Samarium Sm 153 lexidronam pentasodium contains radioactive substance kill cancer cell . Peripheral blood stem cell transplant use stem cell patient may able replace immune cell destroy chemotherapy radioactive drug use kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose samarium Sm 153 lexidronam pentasodium give together high-dose melphalan treat patient multiple myeloma undergoing stem cell transplant .</brief_summary>
	<brief_title>Samarium Sm 153 Lexidronam Pentasodium High-Dose Melphalan Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : - To find maximum tolerate dose samarium Sm 153 lexidronam pentasodium give fix high-dose melphalan condition regimen autologous peripheral blood stem cell transplantation patient multiple myeloma . ( Phase I ) - To assess response rate regimen patient . ( Phase II ) OUTLINE : This phase I , dose-escalation study samarium Sm 153 lexidronam pentasodium follow phase II study . - Phase I : Patients receive samarium Sm 153 lexidronam pentasodium IV day -14 -10 . Patients also receive melphalan IV day -1 . Patients undergo peripheral blood stem cell transplantation day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously daily begin day 6 continue blood count recover . - Phase II : Patients receive samarium Sm 153 lexidronam pentasodium MTD determine phase I . Blood sample collect periodically determine clearance samarium Sm 153 lexidronam pentasodium bone marrow dosimetry .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma require treatment Must least 2 x 10^6 CD34+ cell collect peripheral blood stem cell transplantation PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status ( PS ) 02 ( ECOG PS &gt; 2 allow secondary neuropathy acute bone event ) Direct bilirubin ≤ 2.0 mg/dL Alkaline phosphatase ≤ 750 μ/L Creatinine ≤ 3.0 mg/dL Ejection fraction ≥ 45 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study therapy Exclusion criterion : DLCO &lt; 50 % FVC &lt; 50 % FEV_1 &lt; 50 % Active malignancy exception nonmelanoma skin cancer Uncontrolled infection NYHA class IIIIV cardiac disease PRIOR CONCURRENT THERAPY : May may receive prior chemotherapy At least 3 week since prior chemotherapy Cyclophosphamide pulse stem cell collection allow At least 4 week since prior biologic therapy At least 2 week since prior bisphosphonates bisphosphonates maybe resume 1 month poststudy treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>